quarta-feira, 7 de outubro de 2026
PesquisarExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· February 27, 2026

Stocks Retreat on AI Disruption Concerns and Geopolitical Risks

View original at nasdaq.com
Stocks Retreat on AI Disruption Concerns and Geopolitical Risks The S&P 500 Index ($SPX) (SPY) today is down -0.61%, the Dow Jones Industrial Average ($DOWI) (DIA) is down -1.17%, and the Nasdaq 100 Index ($IUXX) (QQQ) is down -0.41%…
Opening lines of the source · short snapshot — read the full document at the original

O que extraímos desta fonte

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Threatened military strikes if Iran fails to comply with nuclear demands

    80% confidence
  • Considering limited military strike on Iran to pressure nuclear deal

    80% confidence
  • Gave Iran March 1-6 deadline for agreement over nuclear activities

    80% confidence
  • S&P earnings growth expected to climb 8.4% in Q4, marking tenth consecutive quarter of year-over-year growth

    80% confidence
  • Excluding Magnificent Seven stocks, Q4 earnings expected to increase 4.6%

    80% confidence
  • Threatened to raise global tariff rate to 15% from 10%

    80% confidence
  • Doubled down on commitment to tariffs in State of the Union address

    80% confidence

Data points we hold from this source

Dell Technologies · operating income3.54 billion_USD

Citado nestas reportagens da Via News

O que sabemos · a inteligência por trás desta página
Ao vivo do substrato
O que estamos a ver
Autumn 2026 Biopharma Catalyst Season: Late-Breaking Data, FDA Milestones and the Rise of AI-Designed Drugs
Late-September and early-October 2026 conferences (EASD, EADV, IGCS) brought a cluster of positive late-breaking trial readouts. These covered obesity and metabolic disease (Novo Nordisk's CagriSema), immunology (Lilly's EBGLYSS, tulisokibart) and oncology (Rina-S, Agenus BOT+BAL). Ahead lie hard regulatory catalysts, led by the 14 Nov 2026 FDA PDUFA date for ivonescimab. At the same time, Insilico-style AI-designed drugs such as rentosertib are showing anti-aging signals. That points to AI-driven drug discovery moving from concept toward clinical validation. Unrelated tech and regulatory items (Tesla Cybercab probe, xAI litigation, OpenAI agent incident) and the speculative QAIAx claims are peripheral to this story.
A nossa leitura dos dados ›
Sinais que acompanhamos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Padrões que observamos ›
Onde as fontes divergem
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Sinalizamos conflitos abertamente ›
Verificado recentemente
✓ Verificado com a fonte original
4,986
factos rastreados à sua fonte — e sinalizamos os que não se confirmam.
101 entidades acompanhadas4,986 factos verificados com a fonte5,362 documentos-fonte arquivados
Consulte estes dados → isubstrate.com
Stocks Retreat on AI Disruption Concerns and Geopolitical Risks — Source | Via News | pt.VIA.NEWS